close

Avanir Pharmaceuticals, a pharmaceutical company, focuses on developing, acquiring, and commercializing therapeutic products for the treatment of chronic diseases primarily in the United States. The company's product candidates address therapeutic markets that include the central nervous system and inflammatory diseases. Its lead product candidate Zenvia, a Phase III clinical development stage product for the treatment of pseudobulbar affect (PBA) and diabetic peripheral neuropathic pain (DPN pain). The company's commercialized product, Abreva, an over-the-counter product for the treatment of cold sores, which is marketed by GlaxoSmithKline Consumer Healthcare in North America. Its inflammatory disease program, which targets macrophage migration inhibitory factor is partnered with Novartis International Pharmaceutical, Ltd. Avanir Pharmaceuticals was founded in 1988 and is headquartered in Aliso Viejo, California.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	3.15
Volume	(mio) 1.53
Volume Avg	(mio) 1.67
52 Week High	4.80
52 Week Low	1.77
PE	N/A
PE (group average)	39
EPS Year	-0.52
EPS change Q/Q	-9.09%
EPS change Q/Q Yr ago	-50%
EPS change Q/Q next Q est	-9.09%
EPS change Y/Y	-25.64%
REV change Q/Q	-22.22%
REV change Q/Q Yr ago	40%
EPS next Q est	-0.11
EPS next Y est	-0.19
Divident Annual	0.00
Dividend Yield	0%